Sec Form 4 Filing - Cardama Alfonso Quintas @ TCR2 THERAPEUTICS INC. - 2022-11-17

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Cardama Alfonso Quintas 2. Issuer Name and Ticker or Trading Symbol TCR2 THERAPEUTICS INC. [ TCRR] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Medical Officer (Last) (First) (Middle) C/O TCR2 THERAPEUTICS, 100 BINNEY STREET 3. Date of Earliest Transaction (MM/DD/YY) 11/17/2022 (Street) CAMBRIDGE, MA02142 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 46,915 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 16.11 11/17/2022 D 5,799 ( 1 ) 04/10/2029 Common Stock 5,799 $ 0( 2 ) 0 D Restricted Stock Unit (right to buy) ( 3 ) 11/17/2022 A 1,933 ( 4 ) ( 4 ) Common Stock 1,933 $ 0( 2 ) 1,933 D Stock Option (right to buy) $ 16.11 11/17/2022 D 205,503 ( 1 ) 04/10/2029 Common Stock 205,503 $ 0( 5 ) 0 D Restricted Stock Unit (right to buy) ( 3 ) 11/17/2022 A 68,501 ( 4 ) ( 4 ) Common Stock 68,501 $ 0( 5 ) 68,501 D Stock Option (right to buy) $ 16.1 11/17/2022 D 3,308 ( 6 ) 12/18/2029 Common Stock 3,308 $ 0( 7 ) 0 D Restricted Stock Unit (right to buy) ( 3 ) 11/17/2022 A 1,103 ( 8 ) ( 8 ) Common Stock 1,103 $ 0( 7 ) 1,103 D Stock Option (right to buy) $ 16.1 11/17/2022 D 68,792 ( 6 ) 12/18/2029 Common Stock 68,792 $ 0( 9 ) 0 D Restricted Stock Unit (right to buy) ( 3 ) 11/17/2022 A 22,931 ( 8 ) ( 8 ) Common Stock 22,931 $ 0( 9 ) 22,931 D Stock Option (right to buy) $ 31.83 11/17/2022 D 4,486 ( 10 ) 12/09/2030 Common Stock 4,486 $ 0( 11 ) 0 D Restricted Stock Unit (right to buy) ( 3 ) 11/17/2022 A 816 ( 12 ) ( 12 ) Common Stock 816 $ 0( 11 ) 816 D Stock Option (right to buy) $ 31.83 11/17/2022 D 96,514 ( 10 ) 12/09/2030 Common Stock 96,514 $ 0( 13 ) 0 D Restricted Stock Unit (right to buy) ( 3 ) 11/17/2022 A 17,548 ( 12 ) ( 12 ) Common Stock 17,548 $ 0( 13 ) 17,548 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Cardama Alfonso Quintas C/O TCR2 THERAPEUTICS 100 BINNEY STREET CAMBRIDGE, MA02142 Chief Medical Officer Signatures /s/ Margaret Siegel as Attorney-in-Fact 11/18/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )This cancelled option vested 25% on January 1, 2020 and the remaining 75% vests in 36 substantially equal monthly installments thereafter. ( 2 )On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on April 11, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 1,933. ( 3 )Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration. ( 4 )The restricted stock units will vest 98% on December 1, 2022, and 2% on December 1, 2023. ( 5 )On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on April 11, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 68,501. ( 6 )This cancelled option vested 25% on January 1, 2021 and the remaining 75% vests in 36 substantially equal monthly installments thereafter. ( 7 )On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 19, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 1,103. ( 8 )73% of these RSUs will vest on December 1, 2022, 25% will vest on December 1, 2023 and the remaining 2% will vest on December 1, 2024. ( 9 )On November 17, 2022, the issuer cancelled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 19, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 22,931. ( 10 )This cancelled option vested 25% on January 1, 2022 and the remaining 75% vests in 36 substantially equal monthly installments thereafter. ( 11 )On November 17, 2022, the issuer cancelled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 10, 2020. In exchange for such stock option, the reporting person received restricted stock units in the amount of 816. ( 12 )48% of these RSUs will vest on December 1, 2022, 25% will vest on December 1, 2023, another 25% will vest on December 1, 2024 and the remaining 2% will vest on December 1, 2025. ( 13 )On November 17, 2022, the issuer cancelled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 10, 2020. In exchange for such stock option, the reporting person received restricted stock units in the amount of 17,548.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.